logc-8k_20220617.htm
false 0001664106 0001664106 2022-06-17 2022-06-17

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 17, 2022

 

 

LOGICBIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

 

001-38707

 

47-1514975

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

65 Hayden Avenue,

2nd Floor

Lexington, MA

 

02421

(Address of principal executive offices)

 

(Zip Code)

 

(617) 245-0399

(Registrant’s telephone number, including area code)

 

n/a

(Former name, former address and formal fiscal year, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

LOGC

 

The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 5.07     Submission of Matters to a Vote of Security Holders.

LogicBio Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders on June 17, 2022. The stockholders (i) elected three Class I directors to the Company’s Board of Directors (the “Board”) to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal; and (ii) ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

 

(i)

The Class I directors elected to the Board, as well as the number of votes for, votes against, abstentions and broker non-votes with respect to each of these individuals, are set forth below:

 

Director

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

Mark Enyedy

 

11,054,240

 

2,115,732

 

21,523

 

8,725,727

J. Jeffrey Goater

 

12,358,249

 

811,423

 

21,823

 

8,725,727

Mark Kay

 

11,581,609

 

1,588,168

 

21,718

 

8,725,727

 

(ii)

The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 received the following votes:

 

Votes For:

21,115,950

Votes Against:

85,311

Abstentions:

715,961


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 21, 2022

 

LOGICBIO THERAPEUTICS, INC.

 

 

By: /s/ Cecilia Jones

Name: Cecilia Jones

Title: Chief Financial Officer